References 1. Stillfried GE, Saunders DN, Ranson M: Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. Breast Cancer Res 2007,9(1):R14.PubMedCrossRef 2. Nguyen DH, Hussaini IM, Gonias SL: Binding of urokinase-type plasminogen activator

to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 1998,273(14):8502–8507.PubMedCrossRef 3. Aguirre GJ, Kovalski K, Ossowski L: Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999,147(1):89–104.CrossRef 4. Kobayashi H, Shinohara H, Takeuchi K, Itoh M, Fujie M, Saitoh M: Inhibition of the soluble and the tumor cell receptor-bound

#Citarinostat cell line randurls[1|1|,|CHEM1|]# plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis. Cancer Res 1994,54(3):844–849.PubMed 5. Kobayashi H, Suzuki M, Tanaka Y, Hirashima Y, Terao T: Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C- and MEK/ERK/c-Jun-dependent signaling pathways. J Biol Chem 2001,276(3):2015–2022.PubMedCrossRef 6. Zhao Xiaoliang, Sun Xin, Gao Feng, Luo Jie, Sun Zhijun: Effects of ulinastatin and docataxel on breast tumor growth Selleckchem Emricasan and expression of IL-6, IL-8, and TNF-a. Journal of Experimental & Clinical Cancer Research 2011, 30:22.CrossRef 7. Sun ZJ, Yu T, Chen JS: Effects of Ulinastatin and Cyclophosphamide on the Growth of Xenograft Breast Cancer and Expression of CXCR4 and MMP-9 in Cancers. The Journal of International Medical Research 2010, 38:967–976.PubMed 8. Gao F, Sun ZJ: Progress in the correlation of vascular endothelial growth factor C and lymphangiogenesis and lymph node metastasis in breast cancer. Chongqing Medical Journal 2010, (07):819–821. 9. Mahanivong C, Yu J, Huang S: Elevated urokinase-specific

surface receptor PRKD3 expression is maintained through its interaction with urokinase plasminogen activator. Mol Carcinog 2007,46(3):165–175.PubMedCrossRef 10. Sliva D, Rizzo MT, English D: Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem 2002,277(5):3150–3157.PubMedCrossRef 11. Kanse SM, Benzakour O, Kanthou C, Christine K, Roger Lijnen H, Preissner KT: Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. Arterioscler Thromb Vasc Biol 1997,17(11):2848–2854.PubMedCrossRef 12. Konakova M, Hucho F, Schleuning WD: Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction. Eur J Biochem 1998,253(2):421–429.PubMedCrossRef 13.